Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa

Journal of Dermatological Treatment

Volumn 23, Issue 4, 2012, Pages 284-289

  Van Rappard, Dominique C ^a   Leenarts, Marjolein F E ^a   Meijerink Van 'T Oost, Leonie ^b   Mekkes, Jan R ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

Adalimumab; Hidradenitis suppurativa; Infliximab; TNF inhibitor

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INJECTION PAIN; MALE; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE INDEX; RETROSPECTIVE STUDY; SARTORIUS SCORE; SCORING SYSTEM; SUPPURATIVE HIDRADENITIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DERMATOLOGIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863886830     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.571657     Document Type: Article

References (22)

1. Wiseman MC. Hidradenitis suppurativa: A review. Dermatol Ther. 2004;17:50-54.
2. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: A study of 61 cases. J Am Acad Dermatol. 2007;56:621-623.
3. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: A comprehensive review. J Am Acad Dermatol. 2009;60: 539-561.
4. Bieniek A, Matusiak L, Okulewicz-Gojlik D, Szepietowski JC. Surgical treatment of hidradenitis suppurativa: Experiences and recommendations. Dermatol Surg. 2010;36:1998-2004.
5. Keating GM, Perry CM. Infliximab: An updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002;16:111-148.
6. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51: 534-542.
7. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: Response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-326.
8. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol. 2009;89:595-600.
9. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217.
10. Lasocki A, Sinclair R, Foley P, Saunders H. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51:186-190.
11. Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49:950-955.
12. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. nt J Dermatol. 2010;49:1445-1449.
13. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501-504.
14. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol. 2008; 158:370-374.
15. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211-213.
16. Sartorius K, Killasli H, Heilborn J, Jemec GB, Lapins J, Emtestam L. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol. 2010;162: 1261-1268.
17. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161: 831-839.
18. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809-813.
19. Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198:261-264.
20. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
21. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009;3: 77-97.
22. NVDV Guideline Committee. Dutch guideline acneiform dermatoses: HIDRADENITIS Suppurativa. NVDV; 2010 (www. huidarts.info